SNY - Sanofi: A Leader In Life-Saving Vaccines And Treatments

2024-06-14 05:06:33 ET

Summary

• In recent weeks, Sanofi has pleased investors with progress in the development of its pipeline of experimental drugs.
• On May 20, 2024, SNY announced additional results from a Phase 3 clinical trial that demonstrated Dupixent's greater efficacy in COPD treatment relative to my expectations.
• Dupixent sales amounted to 2.84 billion euros in the first three months of 2024, up 22.4% year-on-year.
• The French pharmaceutical company has a strong balance sheet, a dividend yield of 4.21%, and has been showing steady year-on-year revenue growth.
• Thus, I'm initiating coverage of Sanofi with a"buy" rating.

Sanofi (SNY) (SNYNF) is one of the largest pharmaceutical companies in Europe, with a leading position in the global anti-inflammatory therapeutics market.

Investment thesis

Wall Street's indifference to France's largest pharmaceutical company is reflected in its share price continuing to move sideways despite its rich pipeline of approved and experimental medicines, rising dividend payouts, and relatively low debt....

For further details see: